Adequacy of Pain Treatment in Radiotherapy

NCT ID: NCT03550599

Last Updated: 2019-01-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-03-01

Study Completion Date

2019-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim of the study is to evaluate adequacy of pain treatment in oncologic patients, accessing to Radiotherapy Unit

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prescription of analgesic drugs is a basic topic in cancer patients, but undertreatment is common. The aim of the study is to analyse pain control and adequacy of antalgic treatments in patients coming to Radiotherapy Unit for radiation treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Pain Analgesic Drugs

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients accessing to Radiotherapy Unit

patients accessing to Radiotherapy Unit for oncologic treatment

Patients accessing to Radiotherapy Unit

Intervention Type OTHER

No intervention; information about patient and disease characteristics will be recorded as well as information about pain and analgesic treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patients accessing to Radiotherapy Unit

No intervention; information about patient and disease characteristics will be recorded as well as information about pain and analgesic treatment

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- patients accessing to Radiotherapy Unit for radiation treatment (both palliative or with radical intent) with diagnosis of primitive or metastatic cancer;

Exclusion Criteria

\- Concomitant diseases that can affect reliability of collected data
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

IRCCS Azienda Ospedaliero-Universitaria di Bologna

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Alessio Giuseppe Morganti

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alessio G Morganti, MD

Role: PRINCIPAL_INVESTIGATOR

Radiation Oncology Center, Departement of Experimental, Diagnostic and Speciality Medicine-DIMES, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine- DIMES, University of Bologna, S.Orsola-Malpighi Hospital

Bologna, BO, Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Alessio G Morganti, MD

Role: CONTACT

0512143564 ext. +39

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Alessio G Morganti, MD

Role: primary

0512143564 ext. +39

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ARISE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Safety of Fentanyl TAIFUN Treatment
NCT00822614 UNKNOWN PHASE3